Structure and function studies of glucagon-like peptide-1 (GLP-1): the designing of a novel pharmacological agent for the treatment of diabetes

Authors

  • Hongxiang Hui,

    1. Division of Endocrinology and Metabolism (H.H, R.P.), and Division of Cardiology (X.Z.), Cedars-Sinai Medical Center, Los Angeles, California, and University of California Los Angeles (H.H., R.P.), Los Angeles, California
    Search for more papers by this author
  • Xiaoning Zhao,

    1. Division of Endocrinology and Metabolism (H.H, R.P.), and Division of Cardiology (X.Z.), Cedars-Sinai Medical Center, Los Angeles, California, and University of California Los Angeles (H.H., R.P.), Los Angeles, California
    Search for more papers by this author
  • Riccardo Perfetti

    Corresponding author
    1. Division of Endocrinology and Metabolism (H.H, R.P.), and Division of Cardiology (X.Z.), Cedars-Sinai Medical Center, Los Angeles, California, and University of California Los Angeles (H.H., R.P.), Los Angeles, California
    • Div. Endocrinology & Diabetes and Metabolism, Cedars-Sinai Medical Center, 8723 Alden Drive, SSB #290, Los Angeles, CA 90048, USA.
    Search for more papers by this author

Abstract

Glucagon-like peptide-1 (GLP-1) is a proglucagon-derived peptide secreted from gut endocrine cells in response to nutrient ingestion. The multifaceted actions of GLP-1 include the following: (1) the stimulation of insulin secretion and of its gene expression, (2) the inhibition of glucagon secretion, (3) the inhibition of food intake, (4) the proliferation and differentiation of beta cells, and (5) the protection of beta-cells from apoptosis. The therapeutic utility of the native GLP-1 molecule is limited by its rapid enzymatic degradation by a serine protease termed dipeptidyl peptidase-IV (DPP-IV). The present article reviews the research studies aimed at elucidating the biosynthesis, metabolism, and molecular characteristics of GLP-1 since it is from these studies that the development of a GLP-1-like pharmacological agent may be derived. Copyright © 2005 John Wiley & Sons, Ltd.

Ancillary